CJC-1295 with DAC, 2mg
Price range: $47.95 through $479.50
CJC-1295 with DAC is a synthetic modified peptide compound studied for its interactions with growth hormone-releasing hormone (GHRH) receptor pathways in experimental models. The Drug Affinity Complex (DAC) modification — a maleimidopropionyl-lysine moiety at the C-terminus — is studied for its capacity to reversibly… CAS: 446262-90-4 | Formula: C165H269N47O46 | Content: 2mg per vial | Research use only | Third-party lab tested.
Buy CJC-1295 with DAC, 2mg – Swiss Chems USA
CJC-1295 with DAC, 2mg — Research Overview
CJC-1295 with DAC is a synthetic modified peptide compound studied for its interactions with growth hormone-releasing hormone (GHRH) receptor pathways in experimental models. The Drug Affinity Complex (DAC) modification — a maleimidopropionyl-lysine moiety at the C-terminus — is studied for its capacity to reversibly bind albumin in experimental systems, producing extended stability compared to the unmodified CJC-1295 variant. The compound is designed with a 30-amino acid sequence structure incorporating four amino acid substitutions that confer enhanced protease resistance relative to native GHRH(1-29). Research applications include GHRH receptor pathway studies, growth hormone secretagogue signalling research, and comparative DAC-modified versus unmodified peptide pharmacology.
- High Purity – 99% Purity Guaranteed
- Independently Lab Tested
- Research Grade Quality
- For Laboratory Research Use Only
Intended use: This material is supplied for laboratory and in-vitro research only. It is not a drug, food, or cosmetic and is not intended for human or animal consumption.
CJC-1295 with DAC, 2mg Chemical Properties
| Property | Specification |
|---|---|
| Chemical Formula | C165H269N47O46 |
| Synonyms | CJC1295 With DAC, 446262-90-4 |
| Molar Mass | 3647.2 g/mol |
| CAS Number | 446262-90-4 |
| PubChem CID | 91971820 |
| Total Compound Content | 2mg per vial |
| Shelf Life | 36 months |
CJC-1295 with DAC, 2mg Research Applications
CJC-1295 with DAC is a synthetic 30-amino acid GHRH analogue studied for selective receptor affinity and extended stability in laboratory research models. The compound incorporates four amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) that confer enhanced protease resistance relative to native GHRH(1-29), and a Drug Affinity Complex (DAC) modification at the C-terminus studied for its capacity to reversibly bind albumin in experimental systems, producing significantly extended peptide stability relative to the non-DAC CJC-1295 variant. Laboratory research has examined its growth hormone secretagogue signalling properties — including proposed modulation of pituitary GHRH receptor pathways and downstream IGF-1 axis signalling — in cell-based and in vivo experimental models. Comparative research protocols frequently pair CJC-1295 with DAC against the non-DAC variant to characterise the contribution of the albumin-binding modification to receptor engagement duration and downstream signalling profiles. Independently third-party HPLC-tested; COA available per batch.
CJC-1295 with DAC, 2mg Frequently Asked Questions
What is the Drug Affinity Complex (DAC) modification and how does it affect CJC-1295’s stability in research models?
The DAC modification in CJC-1295 is a maleimidopropionyl-lysine moiety incorporated at the C-terminus of the peptide sequence, studied for its capacity to reversibly bind cysteine-34 of albumin in experimental systems. This albumin-binding interaction is studied for its role in significantly extending the peptide’s stability in biological research models relative to the non-DAC CJC-1295 variant, making the DAC form a standard research tool in protocols requiring sustained receptor pathway engagement over extended experimental timelines.
How do the four amino acid substitutions in CJC-1295 differ from native GHRH(1-29)?
CJC-1295 incorporates D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27 relative to native GHRH(1-29), substitutions studied for their capacity to confer enhanced resistance to proteolytic degradation while preserving GHRH receptor binding affinity. These modifications are examined in comparative structure-activity research contrasting CJC-1295’s stability and receptor binding profile against native GHRH(1-29) and other GHRH analogues.
What advantages does the 10-vial KIT format provide for extended research programs?
The 10-vial KIT format is particularly useful for longitudinal investigations, repeated-dose studies, multi-arm experimental designs, pharmacokinetic research, and chronic pathway-signaling programs requiring consistent compound availability across multiple study phases. Individually sealed vials allow compound to remain lyophilized until needed, supporting stability throughout extended research timelines. The use of matched-batch material across all ten vials also helps minimize variability between experimental sessions, making the KIT format well suited to long-duration receptor-signaling and comparative pharmacology studies.
Research Use Disclaimer
All product information is provided for educational and laboratory research reference only. Any form of introduction into humans or animals is prohibited. Handle only in licensed research settings in accordance with applicable laws and institutional protocols.
| Weight | 1 lbs |
|---|---|
| Cjc 1295 With Dac 2Mg |
KIT (10 vials) ,Vial |
Related products
BPC-157 (0.5mg/capsule), 60 Capsules
Original price was: $114.95.$85.95Current price is: $85.95.
FTPP (Adipotide) 5mg
Price range: $63.95 through $639.50
MGF without PEG 2mg
Price range: $29.99 through $299.90
MOTS-C 10mg
Price range: $69.95 through $699.50
PEG MGF 2mg
Price range: $47.95 through $479.50
PT-141 (Bremenalotide), 10mg
Price range: $49.99 through $499.90
Reviews
There are no reviews yet.